📊 KAPA Key Takeaways
Is KAPA a Good Investment? Thesis Analysis
Kairos Pharma is a pre-revenue pharmaceutical company with no reported sales and significant operating losses of $5.6M paired with negative cash flow of $3.4M annually. While the company maintains strong liquidity with $4.5M in cash and minimal debt, this provides only ~1.3 years of operational runway at current burn rates. Without demonstrated revenue or clear commercialization catalysts, the fundamental outlook remains highly distressed.
Why Buy KAPA? Key Strengths
- Strong cash position of $4.5M with exceptional liquidity (27x current ratio)
- Minimal debt burden with 0.00x debt-to-equity ratio
- Low liability base ($992K) relative to equity ($6.3M)
KAPA Investment Risks to Consider
- Zero reported revenue indicates pre-commercial stage with unproven market traction
- Significant operating losses (-$5.6M) and negative operating cash flow (-$3.4M) with limited visibility to profitability
- Runway of approximately 1.3 years at current burn rate creates near-term financing and dilution risk
- Negative ROE (-85.9%) and ROA (-83.3%) indicating value destruction
- No insider buying activity in last 90 days suggests lack of confidence
Key Metrics to Watch
- Revenue recognition and QoQ growth trajectory
- Monthly cash burn rate and extension of runway
- Operating cash flow progression toward positive inflection
- Clinical trial advancement and regulatory approval status
- Dilution from future financing and cash position depletion
KAPA Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 27.07x current ratio provides a solid financial cushion.
KAPA Profitability Ratios
KAPA vs Healthcare Sector
How Kairos Pharma, LTD. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is KAPA Overvalued or Undervalued?
Based on fundamental analysis, Kairos Pharma, LTD. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
KAPA Balance Sheet & Liquidity
KAPA 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Kairos Pharma, LTD.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.23 indicates the company is currently unprofitable.
KAPA Growth Metrics (YoY)
KAPA Capital Allocation
KAPA SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Kairos Pharma, LTD. (CIK: 0001962011)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KAPA
What is the AI rating for KAPA?
Kairos Pharma, LTD. (KAPA) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are KAPA's key strengths?
Claude: Strong cash position of $4.5M with exceptional liquidity (27x current ratio). Minimal debt burden with 0.00x debt-to-equity ratio.
What are the risks of investing in KAPA?
Claude: Zero reported revenue indicates pre-commercial stage with unproven market traction. Significant operating losses (-$5.6M) and negative operating cash flow (-$3.4M) with limited visibility to profitability.
What is KAPA's revenue and growth?
Kairos Pharma, LTD. reported revenue of N/A.
Does KAPA pay dividends?
Kairos Pharma, LTD. does not currently pay dividends.
Where can I find KAPA SEC filings?
Official SEC filings for Kairos Pharma, LTD. (CIK: 0001962011) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KAPA's EPS?
Kairos Pharma, LTD. has a diluted EPS of $-0.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KAPA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Kairos Pharma, LTD. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KAPA stock overvalued or undervalued?
Valuation metrics for KAPA: ROE of -85.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KAPA stock in 2026?
Our dual AI analysis gives Kairos Pharma, LTD. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KAPA's free cash flow?
Kairos Pharma, LTD.'s operating cash flow is $-3.4M, with capital expenditures of N/A.
How does KAPA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -85.9% (avg: 15%), current ratio 27.07 (avg: 2).